DAIC

APRIL 18, 2024

Two articles and an accompanying editorial in Heart Rhythm , the official journal of the Heart Rhythm Society, the Cardiac Electrophysiology Society , and the Pediatric & Congenital Electrophysiology Society , published by Elsevier , address the controversy and recommend shortening the blanking period.

Atrial Fibrillation 111

Atrial Fibrillation Ablation Heart Rhythm Article 111

Circulation: Arrhythmia and Electrophysiology

MARCH 21, 2025

Circulation: Arrhythmia and Electrophysiology, Ahead of Print.

Atrial Fibrillation 40

Atrial Fibrillation Electrophysiology Arrhythmia Pulmonary 40

DAIC

JULY 24, 2024

Volta Medical has announced it has entered into a Joint Development Agreement with GE Healthcare to enhance arrhythmia procedures with artificial intelligence (AI)-driven electrophysiology technologies. Our mission to combat complex heart rhythm diseases relies on optimizing interoperability.

Atrial Fibrillation 105

Atrial Fibrillation AFIB Ablation Technology 105

DAIC

MARCH 1, 2024

“The entire digital electrocardiogram signal performed significantly better than a few of its components,” said Chugh, who is also the Pauline and Harold Price Chair in Cardiac Electrophysiology Research and associate director in the Smidt Heart Institute. “We

Cardiac Arrest 111

Cardiac Arrest Electrocardiogram Defibrillator Electrophysiology 111

DAIC

DECEMBER 29, 2023

Unlike paroxysmal AF, which describes symptoms that last for seven days or fewer, persistent AF is a sustained arrhythmia that lasts for more than a week 1. Early treatment of persistent AF can reduce the risk of blood clots, stroke, and heart failure, and may prevent the disease from becoming permanent.

Atrial Fibrillation 115

Atrial Fibrillation Ablation Atrial Flutter Blood Clot 115

Circulation: Arrhythmia and Electrophysiology

NOVEMBER 3, 2023

Circulation: Arrhythmia and Electrophysiology, Volume 16, Issue 11 , Page e012043, November 1, 2023. BACKGROUND:In patients with persistent atrial fibrillation (PersAF), catheter ablation aiming for pulmonary vein isolation (PVI) is associated with moderate clinical effectiveness.

Atrial Fibrillation 40

Atrial Fibrillation Pulmonary Quality of Life Ablation 40

Journal of Cardiovascular Electrophysiology

DECEMBER 10, 2024

Objective We report the feasibility, safety, and clinical efficacy of focal monopolar PFA in patients with the origin of their atrial arrhythmia in the SVC. Conclusions In this patient cohort with SVC-triggered atrial arrhythmia, isolation using focal monopolar PFA was feasible, effective, and safe.

Arrhythmia 40

Arrhythmia Ablation Pulmonary Tachycardia 40

Circulation: Arrhythmia and Electrophysiology

DECEMBER 19, 2024

Circulation: Arrhythmia and Electrophysiology, Ahead of Print. The primary end point was any documented atrial arrhythmia lasting 30 seconds after a 3-month blanking period after ablation. to 3.4%]; hazard ratio, 0.66 [95% CI, 0.460.94]).

Atrial Fibrillation 40

Atrial Fibrillation Ablation Arrhythmia Pulmonary 40

Journal of Cardiovascular Electrophysiology

OCTOBER 19, 2023

Although the QDOT MICRO™ Catheter was mainly designed for pulmonary vein isolation (PVI) its versatility to treat atrial fibrillation (AF) and other types of arrhythmias was recently evaluated by the FAST and FURIOUS study series and other studies and will be presented in this article.

Arrhythmia 40

Arrhythmia Ablation Atrial Flutter Atrial Fibrillation 40

Frontiers in Cardiovascular Medicine

FEBRUARY 17, 2025

Backgroundwide antral pulmonary vein isolation (PVI) is effective for treating paroxysmal atrial fibrillation (PAF), although time-demanding. Procedural data and electrophysiology (EP) laboratory times were systematically collected and analyzed.

Atrial Fibrillation 52

Atrial Fibrillation Ablation Laboratory Electrophysiology 52

HeartRhythm

MARCH 12, 2024

A 37-year-old woman with biventricular repair for pulmonary atresia and an intact ventricular septum was referred for an electrophysiological study in the context of recurrent atrial arrhythmias with multiple electrical cardioversions. Her clinical tachycardia was easily inducible and had a cycle length (TCL) of 340 ms.

Congenital Heart Disease 40

Congenital Heart Disease Congenital Heart Disease Electrophysiology 40

Circulation: Arrhythmia and Electrophysiology

DECEMBER 19, 2024

Circulation: Arrhythmia and Electrophysiology, Ahead of Print. Patients with paroxysmal or persistent atrial fibrillation underwent pulmonary vein (PV) isolation under deep sedation or general anesthesia and returned for remapping at 90 days to evaluate chronic durability. paroxysmal, and 58.5% deep sedation) were treated.

Atrial Fibrillation 40

Atrial Fibrillation Ablation Arrhythmia Outcomes 40

Circulation: Arrhythmia and Electrophysiology

NOVEMBER 29, 2024

Circulation: Arrhythmia and Electrophysiology, Volume 17, Issue 12 , Page e013208, December 1, 2024. BACKGROUND:The pentaspline pulsed field ablation catheter achieves pulmonary vein isolation using 8 stacked, pose-specific applications with rotation. versus 6.12.0 mm;P=0.02).

Ablation 40

Ablation Pulmonary Electrophysiology Arrhythmia 40

Circulation: Arrhythmia and Electrophysiology

DECEMBER 16, 2024

Circulation: Arrhythmia and Electrophysiology, Ahead of Print.

Ablation 40

Ablation Atrial Fibrillation Electrophysiology Pulmonary 40

Journal of Cardiovascular Electrophysiology

DECEMBER 7, 2023

Abstract Background The newly introduced nonthermal pulsed field ablation (PFA) is a promising technology to achieve fast pulmonary vein isolation (PVI) with high acute success rates and good safety features. Two tamponades occurred in the PFA while in VHPSD two pts suffered groin bleedings.

Ablation 40

Ablation Pulmonary Arrhythmia Atrial Fibrillation 40

All About Cardiovascular System and Disorders

MARCH 30, 2024

The cyanosis in Ebstein’s anomaly, is usually not due to pulmonary hypertension, but because tricuspid regurgitation jet is directed across the atrial septal defect. This can be a source of cardiac arrhythmia as well. Electrophysiological study will show that, and this pathway can be ablated.

Tricuspid 52

Tricuspid Arrhythmia Congenital Heart Disease Electrophysiology 52

Circulation: Arrhythmia and Electrophysiology

NOVEMBER 23, 2023

Circulation: Arrhythmia and Electrophysiology, Ahead of Print. A contact force–sensing catheter was used to focally deliver PFA/radiofrequency at the pulmonary veins and other predefined sites in the atria. Transmurality was achieved in 95% of targeted sites and 100% at pulmonary veins.

Ablation 40

Ablation Pulmonary Atrial Fibrillation Electrophysiology 40

Journal of Cardiovascular Electrophysiology

MARCH 6, 2024

This novel cryoballoon with adjustable size and low compliance successfully achieves pulmonary vein isolation to treat paroxysmal atrial fibrillation (PAF), providing more options for patients with PAF. This cryoballoon system was proven to be safe and effective for treatment of patients with drug refractory or drug intolerant PAF.

Pulmonary 40

Pulmonary Atrial Fibrillation Outcomes Document 40

Journal of Cardiovascular Electrophysiology

DECEMBER 7, 2023

We present the long-term outcome of catheter ablation (CA) and electrophysiological characteristics in HIV+ AF patients. During first procedure, all received isolation of pulmonary vein (PV) + posterior wall and superior vena cava. After focal ablation of non-PV trigger, no difference in arrhythmia recurrence between two groups [80.6%

Atrial Fibrillation 40

Atrial Fibrillation Ablation Outcomes Arrhythmia 40

Journal of Cardiovascular Electrophysiology

MARCH 27, 2025

Prior studies have demonstrated low rates of arrhythmia recurrence, but little is known about ablation lesion durability. During repeat ablation, ULTC ablation lesions were assessed for electrical block, including segment-based assessment of pulmonary vein (PV) ablation lesions. Arrhythmia outcomes after repeat ablation were evaluated.

Atrial Fibrillation 40

Atrial Fibrillation Ablation Arrhythmia Bicuspid/Mitral 40

Journal of Cardiovascular Electrophysiology

NOVEMBER 21, 2023

Abstract Introduction Pulmonary vein isolations (PVI) are being performed using a high-power, short-duration (HPSD) strategy. The primary endpoint was the 1-year recurrence of any atrial arrhythmia lasting ≥30 s, detected using three 14-day ambulatory continuous ECG monitoring. Procedural and safety endpoints were also evaluated.

Ablation 40

Ablation Pulmonary Atrial Fibrillation Arrhythmia 40

DAIC

MARCH 5, 2024

a global leader in cardiac arrhythmia treatment and part of Johnson & Johnson MedTech , today announced European CE mark approval of the VARIPULSE Platform for the treatment of symptomatic drug refractory recurrent paroxysmal atrial fibrillation ( AF ) using pulsed field ablation (PFA). [ii] Catheter Ablation. Available at: [link].

Ablation 59

Ablation Atrial Fibrillation Atrial Flutter Pulmonary 59

Journal of Cardiovascular Electrophysiology

JANUARY 28, 2024

Abstract Introduction During atrial fibrillation ablation (AFA), achievement of first pass isolation (FPI) reflects effective lesion formation and predicts long-term freedom from arrhythmia recurrence. We aim to determine the clinical and procedural predictors of pulmonary vein FPI.

Ablation 40

Ablation Pulmonary BMI Atrial Fibrillation 40

All About Cardiovascular System and Disorders

OCTOBER 26, 2023

This is the proposed mechanism of precipitation of arrhythmias in Brugada syndrome during febrile episodes. There is a potential risk for drug challenge in that life threatening ventricular arrhythmias could be precipitated. Opinion is divided on the need for electrophysiology study. With proper precautions, risk can be reduced.

Sudden Cardiac Death 52

Sudden Cardiac Death Atrial Fibrillation Electrophysiology Arrhythmia 52

Journal of Cardiovascular Electrophysiology

MARCH 19, 2025

ABSTRACT Introduction Pulmonary vein isolation (PVI) using a cryoballoon is well-established for the treatment of paroxysmal atrial fibrillation (PAF). and freedom from any arrhythmia in 83.5%. However, 1-year efficacy and safety still needs to be proven. Results This study treated 391 patients with the novel cryoballoon.

Atrial Fibrillation 40

Atrial Fibrillation Myocardial Infarction Pulmonary Technology 40

DAIC

DECEMBER 26, 2023

Importantly, the speed and ease with which we were able to isolate the pulmonary veins with the nsPFA 360 catheter was impressive and all patients tolerated the procedure well. Patients will continue to be monitored and evaluated over the coming months to assess safety and effectiveness with the primary safety endpoint at 30 days.

Ablation 59

Ablation Atrial Fibrillation Technology Cardiothoracic 59

Journal of Cardiovascular Electrophysiology

APRIL 2, 2025

The Kaplan-Meier curve of all-atrial arrhythmia-free survival for (A) all persistent patients and (B) patients who underwent PSM conducted to the higher recurrence rate in PVI + group. A total of 457 persistent AF patients from EU-PORIA were included in this trial and Propensity score matched (PSM) analysis was conducted.

Atrial Fibrillation 40

Atrial Fibrillation Ablation Tachycardia Tricuspid 40

Journal of Cardiovascular Electrophysiology

DECEMBER 7, 2023

Abstract Introduction Cryoballoon ablation (CBA) of the left atrial (LA) roof in addition to a pulmonary vein isolation has been expected to improve the clinical outcomes post-atrial fibrillation (AF) ablation. The 1-year Kaplan–Meier atrial arrhythmia free rate estimates were 80.6% 40.5 ± 7.5°C C for Group B, p  < .01)

Ablation 40

Ablation Pulmonary Atrial Fibrillation Arrhythmia 40

DAIC

JUNE 19, 2024

By 1909 ECGs were being used to diagnose cases of arrhythmia; by 1910 to diagnose indicators of a heart attack. The pipeline of algorithms likely to clear regulatory hurdles and enter the cardiac market over the next 12-18 months include those for Pulmonary Hypertension, Cardiac Amyloidosis, Diastolic dysfunction, and Hyperkalaemia.

AFIB 105

AFIB Reimbursement Research Atrial Fibrillation 105

Journal of Cardiovascular Electrophysiology

JANUARY 28, 2024

First-pass isolation, acute pulmonary vein (PV) reconnections, 1-year arrhythmia recurrence, and major complications were assessed. in lower AI group were free from atrial arrhythmia (log rank p  = .334). Of the 270 enrolled patients, 238 completed 1-year follow-up (118 in CLOSE group and 120 in lower AI group).

Atrial Fibrillation 40

Atrial Fibrillation Ablation Arrhythmia Pulmonary 40

Journal of Cardiovascular Electrophysiology

JANUARY 10, 2024

In addition to pulmonary vein isolation (PVI), ablation of DISPERS was performed aiming at homogenizing, dissecting, isolating, or connecting DISPERS areas to nonconducting anatomical structures. After a blanking period of 6 weeks, recurrence of any atrial arrhythmia was documented in 26 patients (52%). After a total of 1.46 ± 0.68

Atrial Fibrillation 40

Atrial Fibrillation Ablation Outpatient Arrhythmia 40

Journal of Cardiovascular Electrophysiology

NOVEMBER 11, 2024

Procedures involved pre-ablation imaging, 3D electroanatomical mapping, pulmonary vein isolation, and targeted ablation strategies focusing on the PLSVC-related ablation. The recurrence rate of arrhythmia postablation was 46.7% The primary endpoints were procedural safety and AF recurrence postablation. years, 31.2%

Atrial Fibrillation 40

Atrial Fibrillation Ablation Outcomes Pulmonary 40

All About Cardiovascular System and Disorders

FEBRUARY 14, 2024

Crochetage sign on ECG in ASD ECG in ASD with severe pulmonary hypertension: Tall R’ in V1, ST depression in inferior leads and V2-V5, and T inversion in inferior leads and V1-V6 are seen. Fragmented QRS is a marker of myocardial scar and consequent arrhythmias in ischemic and nonischemic cardiomyopathy.

Congenital Heart Disease 52

Congenital Heart Disease Congenital Heart Disease VSD 52

Dr. Smith's ECG Blog

APRIL 8, 2016

Bedside ultrasound showed no effusion and moderately decreased LV function, with B-lines of pulmonary edema. IV administration of potassium is indicated when arrhythmias are present or hypokalemia is severe (potassium level of less than 2.5 malignant ventricular arrhythmias are present), rapid replacement of potassium is required.

STEMI 52

STEMI Myocardial Infarction Cardiac Arrest Arrhythmia 52

Circulation: Arrhythmia and Electrophysiology

DECEMBER 20, 2024

Circulation: Arrhythmia and Electrophysiology, Ahead of Print. BACKGROUND:Patients undergoing first-time atrial fibrillation (AF) ablation can benefit from targeting non-pulmonary vein (PV) triggers. Preprocedural identification of high-risk individuals can guide planning of ablation strategy.

Atrial Fibrillation 40

Atrial Fibrillation Ablation Electrophysiology Tachycardia 40

Dr. Smith's ECG Blog

APRIL 8, 2015

Finally, much of this correlates well with The new Canadian Syncope Arrhythmia Risk Score , just published in 2016, results of which are given below in the Annotated Bibliography. The most recent and probably best study is this: Canadian Syncope Arrhythmia Risk Score. Aortic Dissection, Valvular (especially Aortic Stenosis), Tamponade.

Arrhythmia 52

Arrhythmia Outcomes Chest Pain Risk Factors 52

Journal of Cardiovascular Electrophysiology

FEBRUARY 10, 2025

Methods Octogenarians with AF or consecutive atrial tachycardia undergoing index or re-ablation (pulmonary vein isolation [PVI] and ablation beyond PVI with different energy sources) in a single center, were analyzed. Arrhythmia-free survival at 1 year was 72.6%. Outcome data regarding CA in these patients are scarce.

Atrial Fibrillation 40

Atrial Fibrillation Ablation Outcomes Pacemaker 40